Significant mortality, morbidity and resource utilization associated with advanced heart failure in congenital heart disease in children and young adults

2019 ◽  
Vol 209 ◽  
pp. 9-19 ◽  
Author(s):  
Danielle S. Burstein ◽  
Pirouz Shamszad ◽  
Dingwei Dai ◽  
Christopher S. Almond ◽  
Jack F. Price ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congenital Heart Disease ◽  
Young Adults ◽  
Heart Disease ◽  
Resource Utilization ◽  
Congenital Heart ◽  
Advanced Heart Failure ◽  
Children And Young Adults ◽  
Significant Mortality

Pacemaker Implantation as a Risk Factor for Heart Failure in Young Adults with Congenital Heart Disease

2006 ◽  
Vol 29 (4) ◽  
pp. 386-392 ◽  
Author(s):  
JORG NOTHROFF ◽  
KAMBIZ NOROZI ◽  
VALENTIN ALPERS ◽  
JAN O. ARNHOLD ◽  
ARMIN WESSEL ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congenital Heart Disease ◽  
Young Adults ◽  
Risk Factor ◽  
Heart Disease ◽  
Congenital Heart ◽  
Pacemaker Implantation

scholarly journals Pulsed Levosimendan in advanced heart failure due to congenital heart disease: a case series

2020 ◽  
Vol 4 (3) ◽  
pp. 1-6
Author(s):  
James Cranley ◽  
Antonia Hardiman ◽  
Leisa J Freeman
Keyword(s):  
Heart Failure ◽  
Congenital Heart Disease ◽  
Heart Disease ◽  
Congenital Heart ◽  
Case Series ◽  
Advanced Heart Failure ◽  
Good Evidence ◽  
Case Summary ◽  
Acute Decompensation

Abstract Background Levosimendan is a non-adrenergic calcium-sensitizing agent with positive inotropic and vasodilatory effects. Its use in acute decompensation of heart failure is established. Good evidence now exists for repetitive infusions of Levosimendan to improve symptoms and reduce hospitalization in advanced heart failure (AdHF) populations. Its use in heart failure resulting from congenital heart disease is not yet commonplace. Case summary We present three cases in which pulsed Levosimendan was used in the management of AdHF secondary to underlying congenital heart disease. There was symptomatic and biomarker evidence of improvement. Discussion Intermittent Levosimendan may represent a valuable therapy to reduce hospitalization and improve quality of life in adults with congenital heart conditions.

Results of Pulmonary Valve Replacement with a Newly Introduced Bioprosthesis in Children and Young Adults with Congenital Heart Disease

2021 ◽  
pp. 1-4
Author(s):  
Jose M. Arribas-Leal ◽  
Maria Garcia-Vieites ◽  
Antonio Jimenez-Aceituna ◽  
Sergio Canovas-Lopez ◽  
Francisco Gutierrez ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Young Adults ◽  
Heart Disease ◽  
Valve Replacement ◽  
Congenital Heart ◽  
Pulmonary Valve ◽  
Pulmonary Valve Replacement ◽  
Children And Young Adults
Sign in / Sign up

Export Citation Format

Share Document